Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

BOTHELL, Wash., Dec. 13, 2012 /PRNewswire-iReach/ -- MediQuest Therapeutics Inc., a specialty pharmaceutical company focused on inflammatory skin diseases and conditions, today announced that they will be conducting partnering/M&A meetings at the J.P. Morgan 31st Annual Healthcare Conference between January 7th and 10th in San Francisco, regarding its Phase 3 topical formulation, VASCANA, designed to treat Raynaud's Disease, an unmet medical need. MediQuest is also selling/licensing the remainder of its topical assets including a skin lightener, ready for commercialization.  Its topical/non-systemic Onychomycosis drug was out-licensed in August 2012.

(Photo: http://photos.prnewswire.com/prnh/20121213/CG29278)

MediQuest's VASCANA has a Special Protocol Assessment granted by the Federal Food & Drug Administration for a single Phase 3 study involving approximately 150 patients that suffer from moderate to severe symptoms of Raynaud's Syndrome.  VASCANA has a strong safety profile and an extensive intellectual property portfolio with issued patents that run to 2026.   The peak sales in the United States is estimated at about $250 million, as well as similar markets in EU and Asia, with low cost of goods, supported by 2-years of stability data.

Any company interested in learning more about VASCANA can arrange to meet with MediQuest at the J.P. Morgan conference through the below contact information.  

About Raynaud's Disease
An estimated 9-11 million people in the United States suffer from Raynaud's Disease, 2.1 million of which have been diagnosed and are seeking medical treatment. Raynaud's patients can experience severe pain associated with chronic vasospasm episodes in their hands, feet and other extremities.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprie
'/>"/>

SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) has announced ... Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" ... been the topic of fascination since the era of the ... and the Soviet Russia. Earlier even a small glimpse of ...
(Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
... MediSapiens Ltd , a Finnish bioinformatics company, has released the ... use. The data is available through a graphical tool, ... Ltd , allowing exploration of the expression activity of genes ... sequencing of the human genome, understanding which genes are expressed ...
... Systems (NYSE: VAR ) announced today that it ... following the close of regular trading on Thursday, October 27, ... available to all interested parties at 2:00 p.m. PT.  The ... will be available on the company website at: www.varian.com/investor ...
Cached Medicine Technology:Transcriptome Viewer - Comprehensive Genome-wide Map of Human Gene Expression Activity Released for Public by MediSapiens 2Varian Medical Systems Schedules Fourth Quarter FY2011 News Release and Conference Call 2
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... of the mouth by trained health workers can help in ... oral cancer mortality rate. ,A research done by scientists ... to visually screen people for oral cancer in order to ... oral cancer patients. ,Oral cancer is the growth of ...
... gets bacterial infections from the bacteria Pseudomonas.// Treatment ... Research suggests that antibiotic treatment may encourage the ... infection. ,Cystic fibrosis is disease of genetic ... mucus that affects the lungs and can cause ...
... newer form of chicken pox vaccine to// effectively control the ... herpes zoster) is the condition that gets symptoms of rashes ... pain, tingling, and numbness on the area. There may be ... somewhat like chicken pox and is caused by the same ...
... College of Georgia had successfully made a protein// that will ... growth of blood vessels that may lead to obstructed vision ... applied to animals suffering from corneal injury or skin cancer ... two third of its growth. The protein is all set ...
... be at higher risk of cardiovascular disease from the// heightened ... are at higher levels, there had been more reports of ... the days the air contains more pollutant particles, the ability ... in diabetic people. ,Impaired vascular reactions in diabetic ...
... the body from the food being heated in a plastic// ... development of the fetus in womb enough to cause breast ... research, which is published in the current edition of the ... the damage. ,Bisphenol-A (BPA) is a chemical founding the ...
Cached Medicine News:
... capability to quickly deliver up to 250 ... for powerful single-pulse ablation. This type of ... coldest and cleanest CO2 surgical laser available ... with the independent adjustment of pulse energy ...
... is a new CO2 laser system with ... panel and an exclusive design for easy ... SmarXide is the leader in a ... traditional features of Dekas laser devices, like ...
... removal for all skin types, ... for leg and facial veins, ... a large spot sizes with ... treatment. An optional scanner ...
... through an ultra thin flexible 400 - 1000 ... of movement when performing surgery. The MedArt® ... of handpieces. Handpieces are supplied with standard ... Straight and angled fiber guides with different ...
Medicine Products: